Humacyte, Inc.
NASDAQHumacyte, Inc. heads into its Q1 2026 earnings release tomorrow with short sellers dug in at levels that leave little margin for disappointment — and a borrow market that has tightened sharply over the past month. Short interest is running at roughly 24% of the free float, with days to cover above 12. That is a heavily shorted position by any measure. What makes it notable is how…
Snapshot as of 14 May 2026
Humacyte, Inc. heads into its Q1 2026 earnings release tomorrow with short sellers dug in at levels that leave little margin for disappointment — and a borrow market that has tightened sharply over the past…
Humacyte enters the post-earnings session with a familiar weight: revenue missed, the borrow market is tightening, and even the house that stayed bullish just cut its target — all while nearly a quarter of the float…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for HUMA — free to start on ORTEX.
Sign up for free →Open HUMA on ORTEX